Genome‐wide CRISPR‐Cas9 viability screen reveals genes involved in TNF‐α‐induced apoptosis of human umbilical vein endothelial cells
- 14 October 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (6) , 9184-9193
Abstract
Tumor necrosis factor α (TNF‐α), a pivotal cytokine in sepsis, protects the host against pathogens by promoting an inflammatory response while simultaneously inducing apoptosis of the vascular endothelium. Unfortunately, inhibitors targeting certain components of the TNF‐α signaling pathway to reduce cellular apoptosis have failed to translate into clinical applications, partly due to the adverse effects of excessive immunosuppression. In an attempt to discover potential targets in the TNF‐α signaling pathway to modulate moderate inflammation and apoptosis during the development of sepsis, we performed a pooled genome‐wide CRISPR/Cas9 knockout screen in human umbilical vein endothelial cells (HUVECs). Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), B‐cell lymphoma 2 (BCL2), Bcl2‐associated death promoter (BAD), and NLR family member X1 (NLRX1) deficiencies were identified as the effective genetic suppressors of TNF‐α cytotoxicity on a list of candidate regulators. CRISPR‐mediated NLRX1 knockout conferred cellular resistance to challenge with TNF‐α, and NLRX1 could be induced to colocalize with mitochondria following TNF‐α stimulation. Thus, our work demonstrates the advantage of genome‐scale screening with Cas9 and validates NLRX1 as a potential modulator of TNF‐α‐induced vascular endothelial apoptosis during sepsis.Keywords
This publication has 36 references indexed in Scilit:
- Efficient Gene Disruption in Cultured Primary Human Endothelial Cells by CRISPR/Cas9Circulation Research, 2015
- Sepsis: a roadmap for future researchThe Lancet Infectious Diseases, 2015
- NLRX1 Protein Attenuates Inflammatory Responses to Infection by Interfering with the RIG-I-MAVS and TRAF6-NF-κB Signaling PathwaysImmunity, 2011
- Mechanisms of bacterial lipopolysaccharide-induced endothelial apoptosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2003
- The immunopathogenesis of sepsisNature, 2002
- Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patientsCritical Care Medicine, 2001
- Rac1 inhibits TNF‐α‐induced endothelial cell apoptosis: dual regulation by reactive oxygen speciesThe FASEB Journal, 2000
- Adjunctive therapy in sepsis: a critical analysis of the clinical trial programmeBritish Medical Bulletin, 1999
- Lipopolysaccharide Induces Disseminated Endothelial Apoptosis Requiring Ceramide GenerationJournal of Experimental Medicine, 1997
- INTERSEPTCritical Care Medicine, 1996